Cargando…

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies

The recent results of Cardiovascular Outcomes Trials (CVOTs) in type 2 diabetes have clearly established the cardiovascular (CV) safety or even the benefit of two therapeutic classes, Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA) and Sodium-Glucose Co-Transporter-2 inhibitors (SGLT-2i). Publi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ludwig, Lisa, Darmon, Patrice, Guerci, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222529/ https://www.ncbi.nlm.nih.gov/pubmed/32404155 http://dx.doi.org/10.1186/s12933-020-01034-3

Ejemplares similares

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
por: Gourdy, Pierre, et al.
Publicado: (2023)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
por: D'Marco, Luis, et al.
Publicado: (2021)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
por: Zimner Rapuch, Sarah, et al.
Publicado: (2021)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
por: Melo, Miguel, et al.
Publicado: (2021)

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020)

The Holy grail, genes and Number Needed to Treat
por: Herbert, Mel
Publicado: (2007)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
por: Lin, Jialing, et al.
Publicado: (2023)

Commentary: Coronary revascularization therapies and number needed to treat
por: Dimagli, Arnaldo, et al.
Publicado: (2022)

Water fluoridation and hypothyroidism: results of this study need much more cautious interpretation
por: Newton, John N, et al.
Publicado: (2015)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
por: Darsalia, Vladimer, et al.
Publicado: (2018)

GLP-2 cures the gut – What about the liver?
por: Pakarinen, Mikko P.
Publicado: (2019)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Class effect for SGLT-2 inhibitors: a tale of 9 drugs
por: Giugliano, Dario, et al.
Publicado: (2019)

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
por: Scheen, A.J.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tjs1s6pg819irb3f23f5ckrphs